HOME >> BIOLOGY >> NEWS
Nanotech safety needs specific government risk research strategy and funding

WASHINGTON--"Prioritizing nanotechnology risk research isn't rocket science," said Project on Emerging Nanotechnologies chief scientist Andrew Maynard. Dr. Maynard's remark is in his testimony today before the federal government's first public meeting focused exclusively on research needs and priorities for the environmental, health and safety risks of engineered nanoscale materials.

"The specific health and safety questions that are important to be addressed for nanotechnology are reasonably straightforward," according to Maynard. "And a lot already has been published about what we know and do not know about the potential risks and about how to fill existing research gaps."

"Far harder is getting the federal government to take action in three critical areas: first, documenting what relevant risk research exists; second, ensuring that agencies responsible for oversight and related research--the Environmental Protection Agency (EPA), Food & Drug Administration (FDA), National Institute of Environmental Health Sciences (NIEHS), National Institute for Occupational Safety & Health (NIOSH), the Consumer Product Safety Commission (CPSC)--are adequately funded; and third, developing a robust, top-down research plan that can be implemented by the U.S. government and used for collaborations with industry and with researchers in other countries," said Maynard.

During his presentation Maynard mixed a powdered nano calcium and magnesium dietary supplement into a glass of water to help illustrate key risk research questions the federal government needs to tackle: what effect do airborne nanoparticles have on the lungs, do nanoparticles penetrate the skin, what happens to nanoparticles in water, how do they behave in the gastrointestinal tract, and what happens to nanoparticles when they are poured down a drain and enter the waste stream?

Maynard points out that these are "obvious questions" but "ones that should be considered when priorit
'"/>

Contact: Lauren Crowley
lauren.crowley@wilsoncenter.org
202-691-4231
Project on Emerging Nanotechnologies
4-Jan-2007


Page: 1 2

Related biology news :

1. Nanotechnology helps scientists make bendy sensors for hydrogen vehicles
2. FDA Nanotechnology Task Force takes positive step forward
3. A new report, Where Does the Nano Go? End-of-Life Regulation of Nanotechnologies
4. Nanotech hitchhikers in blood
5. Nanotechnology, medicine and bioethics
6. Nanotechnology: consumers must be convinced benefits outweigh risks
7. Nanotechnology requires immediate changes in EPA
8. Nanotechnology provides green path to environmentally sustainable economy
9. Nanotechnology offers hope for treating spinal cord injuries, diabetes and Parkinsons disease
10. Green Nanotechnology: Its Easier Than You Think
11. Nanotechnologys past, present and future: A Congressional perspective

Post Your Comments:
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
Cached News: